Valganciclovir: Clinical Trials

106 trials of Valganciclovir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

58 completed, 19 terminated, 12 recruiting, 7 unknown. 37 Phase 2, 31 Phase 3, 17 Phase 4, 16 Phase 1, 9 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 237Completed 18, Terminated 7, Recruiting 5, Not yet recruiting 3, Active not recruiting 2, Unknown 1, Withdrawn 1
Phase 331Completed 16, Terminated 10, Recruiting 3, Unknown 2
Phase 417Completed 13, Recruiting 2, Unknown 1, Withdrawn 1
Phase 116Completed 10, Terminated 4, Recruiting 1, Unknown 1
Not applicable9Completed 7, Recruiting 1, Withdrawn 1

Follow Valganciclovir: new trials by email Literature Review of Valganciclovir trials Research Report on Valganciclovir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II
Valganciclovir, Ganciclovir (GCV), Placebo - Cytomegalovirus (CMV), Anterior Uveitis
Phase 2Not yet recruitingUniversity of California, San Francisco1172026-11-012026-08-11
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
Valganciclovir - Brain Cancer Metastatic, CMV Viremia
Phase 2RecruitingThe Methodist Hospital Research Institute282026-07-142026-08-10
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
Valganciclovir, Placebo - Cytomegalovirus (CMV) Infection
Phase 2Not yet recruitingWits Health Consortium (Pty) Ltd1302026-02-012026-01-30
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Letermovir, Placebo, Valganciclovir/Ganciclovir - CMV, Lung Transplant Recipient
Phase 4RecruitingUniversity Health Network, Toronto402025-12-242026-02-17
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Valacyclovir (Valtrex), Valganciclovir (Valcyte) - Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Not applicableRecruitingNational Taiwan University Hospital802025-11-272025-12-19
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection
Phase 2 / Phase 3RecruitingColumbia University1502025-09-122026-10-02
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody - Nasopharyngeal Cancinoma (NPC)
Phase 2Not yet recruitingSun Yat-sen University102025-08-192025-08-24
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis - Cytomegalovirus (CMV), Kidney Transplant; Complications
Phase 3RecruitingUniversity of California, San Francisco3602025-07-222026-11-02
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Letermovir, Valganciclovir - Kidney Transplant
Phase 4RecruitingFirst Affiliated Hospital Xi'an Jiaotong University2902025-05-132025-12-05
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
RZ-001, VGCV - Glioblastoma
Phase 1 / Phase 2RecruitingRznomics, Inc.432024-10-082025-09-05
CMV Immunity Monitoring in Lung Transplant Recipients
Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Valganciclovir - Lung Transplant; Complications
Phase 2RecruitingNYU Langone Health502024-09-132026-05-29
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris802024-08-142026-01-02
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
GEN2 + Valganciclovir - Solid Tumor, Adult
Phase 1TerminatedGenVivo, Inc.372024-03-042026-03-13
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
[14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir - Advanced Cancer
Phase 1TerminatedViracta Therapeutics, Inc.82024-02-282025-01-20
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Maribavir, Valganciclovir - Transplant Complication, CMV
Phase 4CompletedMedical University of South Carolina702023-11-062026-04-30
CMV CTLs in Neonates With CMV Infection
CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy - Congenital Cytomegaloviral (CMV) Disease
Phase 2RecruitingNew York Medical College232023-07-012026-10-28
Letermovir for CMV Prevention After Lung Transplantation
Letermovir, Valganciclovir - Lung Transplant, CMV
Phase 2CompletedFernanda P Silveira, MD, MS152021-12-062026-04-09
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
Valganciclovir, Placebo - Major Depressive Disorder
Phase 1 / Phase 2CompletedLaureate Institute for Brain Research, Inc.202021-11-232026-04-21
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Nanatinostat, Valganciclovir, Pembrolizumab - Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma
Phase 1TerminatedViracta Therapeutics, Inc.262021-10-082025-03-12
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
Phase 2TerminatedViracta Therapeutics, Inc.1022021-05-282025-07-28

Showing 20 of 106. Sign in to see all of them.

Conditions studied

Cytomegalovirus Infections (43)  ·  Multiple Acyl Coenzyme A Dehydrogenase Deficiency (9)  ·  Epstein-Barr Virus Infections (6)  ·  HIV Infections (6)  ·  Lymphoproliferative Disorders (4)  ·  Sarcoma, Kaposi (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Cytomegalovirus Retinitis (3)  ·  Glioblastoma (3)  ·  Hearing Loss, Sensorineural (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Nasopharyngeal Carcinoma (3)  ·  AIDS-Related Opportunistic Infections (2)  ·  Castleman Disease (2)  ·  Colitis, Ulcerative (2)

Sponsors

Hoffmann-La Roche (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (9)  ·  University of California, San Francisco (4)  ·  Viracta Therapeutics, Inc. (4)  ·  Duke University (3)  ·  National Cancer Institute (NCI) (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Dr. Ann C.T.M. Vossen (2)  ·  Dr. Reddy's Laboratories Limited (2)  ·  First Affiliated Hospital Xi'an Jiaotong University (2)  ·  HemaQuest Pharmaceuticals Inc. (2)  ·  Jazz Pharmaceuticals (2)  ·  Medical University of South Carolina (2)  ·  Shire (2)  ·  University Health Network, Toronto (2)

Countries

United States (65)  ·  Spain (16)  ·  Canada (14)  ·  France (12)  ·  United Kingdom (12)  ·  Australia (9)  ·  Germany (9)  ·  Austria (8)  ·  Italy (8)  ·  Mexico (7)  ·  Belgium (5)  ·  Brazil (5)  ·  Taiwan (5)  ·  China (4)  ·  Israel (4)

Top investigators

Darrel P Cohen, MD, PhD (3)  ·  John A Gonzales, MD (2)  ·  Robert Yarchoan, M.D. (2)  ·  Abhijit P. Limaye, MD (1)  ·  Adam Lerner, M.D. (1)  ·  Akshjot Puri, M.D. (1)  ·  Albert Park, MD (1)  ·  Alexander T Maskin, MD (1)  ·  Ann CT Vossen, Dr. (1)  ·  Anna Wald, MD, MPH (1)  ·  Anne Marie Oudesluys-Murphy, Prof. Dr. (1)

Results publications

PMID 38700045, PMID 39807668, PMID 20353469, PMID 37530631, PMID 16780548, PMID 17640310, PMID 18039954, PMID 19632953, PMID 19738014, PMID 20547904, PMID 21487108, PMID 21502083, PMID 22694733, PMID 22694755, PMID 23009139, PMID 23196955, PMID 23404447, PMID 23418272, PMID 23593305, PMID 23959519, PMID 24078428, PMID 24174627, PMID 24224707, PMID 24256396, PMID 24656016, PMID 24983306, PMID 25331113, PMID 25560711, PMID 25661673, PMID 25738669, PMID 26416517, PMID 28383392, PMID 28437539, PMID 29166336, PMID 31420397, PMID 31862739, PMID 32276276, PMID 32286644, PMID 32493198, PMID 32504089, PMID 32726431, PMID 33720337, PMID 33740394, PMID 33811823, PMID 33861738, PMID 34864943, PMID 35076931, PMID 35194187, PMID 35761406, PMID 36724434

NIH funding

2015 (3), 2019 (2), 2005 (1), 2017 (1), 2018 (1), 2023 (1), P30AI027763 (1), R01AI184205 (1), R34AI095135 (1), U01AI110658 (1), U01DC014706 (1), UG1EY036344 (1)